Kliniken Essen-Mitte

Interest in Integrative Medicine Among Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study (2017) Hack C, Fasching P, Fehm T, De Waal J, Rezai M, Baier B, Baake G, et al. Journal article Gynecologic oncologists' attitudes and practices relating to integrative medicine: results of a nationwide AGO survey (2017) Klein E, Beckmann M, Bader W, Brucker C, Dobos G, Fischer D, Hanf V, et al. Journal article Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial (2017) Hahnen E, Lederer B, Hauke J, Loibl S, Kroeber S, Schneeweiss A, Denkert C, et al. Journal article Event Announcement 3rd Symposium of the AGO Commission Integrative Medicine: "Integrative Medicine: Holistic Care with Natural Healing Procedures" (2017) Kuemmel S, Hack C Journal article, other Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci (2017) Glubb DM, Johnatty SE, Quinn MCJ, O'Mara TA, Tyrer JP, Gao B, Fasching P, et al. Journal article Can contemporary trials in HER2-negative metastatic breast cancer (mBC) detect overall survival (OS) benefit? (2017) Kuemmel S, Jackisch C, Mueller V, Schneeweiss A, Klawitter S, Lux MP Conference contribution Comparative budget impact assessment of the different breast cancer genomic tests in Germany (2017) Lux MP, Schrauder MG, Hildebrandt T, Nabieva N, Kuemmel S, Blohmer JU Conference contribution A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study (2017) Harbeck N, Saupe S, Jaeger E, Schmidt M, Kreienberg R, Mueller L, Otremba BJ, et al. Journal article The DETECT Study Concept - Metastatic breast cancer and circulating tumor cells (2016) Schramm A, Friedl T, Rack B, Trapp E, Fasching P, Taran FA, Hartkopf A, et al. Conference contribution Randomized, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple negative or luminal B/HER2 normal breast cancer (GENEVIEVE) (2016) Paepke S, Huober J, Sherko K, Eidtmann H, Untch M, Costa SD, Blohmer JU, et al. Conference contribution